LAVA Therapeutics to Join H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

25 June 2024

LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company, has announced that Stephen Hurly, President and Chief Executive Officer, will present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference.

Presentation Details 
Format: Fireside Chat
Date: Tuesday, June 25, 2024
Time: 9:30 AM ET
A webcast of the presentation will be available under the "Events" tab on the investor relations section of the LAVA Therapeutics website. The replay will be accessible for 90 days following the presentation date.

About LAVA Therapeutics

LAVA Therapeutics N.V. is dedicated to advancing its proprietary Gammabody® platform, aiming to develop a range of bispecific gamma-delta T cell engagers. These engagers are designed for the potential treatment of solid tumors and hematologic malignancies. The company specializes in bispecific antibodies engineered to specifically target and destroy cancer cells by activating Vγ9Vδ2 T cell antitumor activities when linked to tumor-associated antigens.

Currently, LAVA is conducting a Phase 1/2a dose escalation study (NCT05369000) to investigate its lead program, LAVA-1207, in patients with metastatic castration-resistant prostate cancer (mCRPC). This study is taking place in both Europe and the United States and includes evaluations of monotherapy as well as combination therapy with interleukin-2 (IL-2). In addition, LAVA is expanding this Phase 1/2a study to include a combination arm with KEYTRUDA® (pembrolizumab) through a clinical collaboration with Merck & Co., Inc., based in Rahway, NJ, USA.

Furthermore, LAVA has licensed PF-08046052 (formerly LAVA-1223) to Pfizer Inc. for its clinical development and potential commercialization. The company’s pipeline also consists of several pre-clinical programs.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!